Back to Search
Start Over
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
- Source :
-
The oncologist [Oncologist] 2019 Jun; Vol. 24 (6), pp. 725-727. Date of Electronic Publication: 2019 Apr 29. - Publication Year :
- 2019
-
Abstract
- Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.<br />Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article.
- Subjects :
- Angiogenesis Inhibitors administration & dosage
Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Combined Chemotherapy Protocols pharmacology
Carcinoma, Renal Cell blood supply
Carcinoma, Renal Cell immunology
Clinical Trials, Phase III as Topic
Drug Synergism
Humans
Kidney Neoplasms blood supply
Kidney Neoplasms immunology
Models, Biological
Neovascularization, Pathologic drug therapy
Neovascularization, Pathologic immunology
Neovascularization, Pathologic prevention & control
Prognosis
Randomized Controlled Trials as Topic
Angiogenesis Inhibitors pharmacology
Antineoplastic Agents, Immunological pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Renal Cell drug therapy
Immunotherapy methods
Kidney Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1549-490X
- Volume :
- 24
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- The oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 31036769
- Full Text :
- https://doi.org/10.1634/theoncologist.2019-0165